CMRA (Comera Life Sciences Holdings) Market Cap: $0.00 Mil (As of Jun. 30, 2026)


What is Comera Life Sciences Holdings Market Cap?

Comera Life Sciences Holdings CMRA Market Cap is $0.00 Mil as of Jun. 30, 2026.

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Comera Life Sciences Holdings's share price for the quarter that ended in Sep. 2023 was $0.2915. Comera Life Sciences Holdings's Shares Outstanding (EOP) for the quarter that ended in Sep. 2023 was 30.74 Mil. Therefore, Comera Life Sciences Holdings's market cap for the quarter that ended in Sep. 2023 was $8.96 Mil.

Comera Life Sciences Holdings's quarterly market cap declined from Mar. 2023 ($20.05 Mil) to Jun. 2023 ($9.34 Mil) and declined from Jun. 2023 ($9.34 Mil) to Sep. 2023 ($8.96 Mil).

Comera Life Sciences Holdings's annual market cap stayed the same from Dec. 2020 ($0.00 Mil) to Dec. 2021 ($0.00 Mil) but then increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($20.55 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Comera Life Sciences Holdings's Enterprise Value for Today is $0.00 Mil.

Comera Life Sciences Holdings  (OTCPK:CMRA) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

Comera Life Sciences Holdings Market Cap Related Terms

Comera Life Sciences Holdings Market Cap Historical Data

* Premium members only.

The historical data trend for Comera Life Sciences Holdings's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Comera Life Sciences Holdings Market Cap Chart

Comera Life Sciences Holdings Annual Data
Trend Dec20 Dec21 Dec22
Market Cap
0.00 0.00 20.55

Comera Life Sciences Holdings Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 26.81 20.55 20.05 9.34 8.96

CMRA vs FREQ, BNTC, IMNN: Market Cap Comparison

For the Biotechnology subindustry, Comera Life Sciences Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Comera Life Sciences Holdings Market Cap vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Comera Life Sciences Holdings's Market Cap distribution charts can be found below:

* The bar in red indicates where Comera Life Sciences Holdings's Market Cap falls into.


Comera Life Sciences Holdings Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Comera Life Sciences Holdings's Market Cap for the fiscal year that ended in Dec. 2022 is calculated as

Market Cap (A: Dec. 2022 )=Share Price (A: Dec. 2022 )*Shares Outstanding (EOP) (A: Dec. 2022 )
=$1.23*16.709
=$20.55

Comera Life Sciences Holdings's Market Cap for the quarter that ended in Sep. 2023 is calculated as

Market Cap (Q: Sep. 2023 )=Share Price (Q: Sep. 2023 )*Shares Outstanding (EOP) (Q: Sep. 2023 )
=$0.2915*30.738
=$8.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Market Cap →
What does a Market Cap of $0.00 Mil mean?
Comera Life Sciences Holdings (CMRA) has a Market Cap of $0.00 Mil as of Jun. 30, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Comera Life Sciences Holdings and its competitors.
Is Comera Life Sciences Holdings' Market Cap too high?
Comera Life Sciences Holdings' current Market Cap is $0.00 Mil.
How does Comera Life Sciences Holdings' Market Cap compare to FREQ and BNTC?
Comera Life Sciences Holdings' Market Cap of $0.00 Mil can be compared against companies in the Biotechnology industry. The industry median Market Cap is 119.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.44, based on 1,428 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Comera Life Sciences Holdings and its competitors. For the Biotechnology industry, the median Market Cap is 119.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Comera Life Sciences Holdings's current Market Cap is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Comera Life Sciences Holdings stock overvalued right now?
Comera Life Sciences Holdings (CMRA) has a current Market Cap of $0.00 Mil. The current Market Cap is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Comera Life Sciences Holdings (CMRA), the current Market Cap is $0.00 Mil as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Comera Life Sciences Holdings Business Description

Address 12 Gill Street, Suite 4650, Woburn, MA, USA, 01801
Comera Life Sciences Holdings Inc is a pre-clinical biotechnology company dedicated to promoting formulation science and technology to transform essential biologic medicines from intravenous to subcutaneous forms. Comera's internal portfolio of proprietary techniques known as the SQore platform is designed to potentially transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, and optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. It also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to the Company's partners' biologic medicines to deliver enhanced formulations that facilitate self-injectable care.